Abstracts tagged "patient"

Abstract Number: 1229 • 2016 ACR/ARHP Annual Meeting
Stakeholder Needs Assessment for a New Model of Care for Pediatric Rheumatology in Ontario
Y. Ingrid Goh^1,2, Michelle Diebold³, Delphine Lim², Saunya Dover¹, Roberta Berard⁴, Kristi Whitney-Mahoney⁵, Christine O'Brien⁵, Daniela Ardelean⁶, Brian Feldman^2,7 and Deborah M. Levy², ¹Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ²Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ³Department of Rheumatology, Children's Hospital, London Health Sciences Centre, London, ON, Canada, ⁴Pediatrics, Children's Hospital, London Health Sciences Centre, London, ON, Canada, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶Pediatric Rheumatology, Children's Hospital, London Health Sciences Centre, London, ON, Canada, ⁷Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: Twenty-five pediatric rheumatologists (PR) service a population of 14 million Ontarians. Patients may travel up to 1500 km to be seen by a PR…
Abstract Number: 1482 • 2016 ACR/ARHP Annual Meeting
Web-Based PILOT Intervention Study to Improve Cardiovascular Risk Knowledge Among Rheumatoid Arthritis Patients
Meenakshi Jolly¹, Eleftheria Steinig², Lisa Walt³ and Rasa Kazkauskaite⁴, ¹Rush, Chicago, IL, ²Division of Rheumatology, Rush University Medical Center, Chicago, IL, ³Rush University, Chicago, IL, ⁴Rush University, chicago, IL
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of mortality in rheumatoid arthritis (RA), underscoring the importance of CVD prevention. The rates of screening and…
Abstract Number: 1506 • 2016 ACR/ARHP Annual Meeting
One Third of Patients with Established Rheumatoid Arthritis (RA) Are Correctly Vaccinated Against Influenza and Pneumococcus and This Is Increasing: 3 Year Longitudinal Assessment of 776 Patients
Laure Gossec¹, Martin Soubrier², Frantz Foissac³, Anna Molto⁴, Thomas Bardin⁵, Francis Berenbaum⁶, Alain Cantagrel⁷, Marie Hélène Cerato⁸, Gerard H. Chales⁹, Isabelle Chary-Valckenaere¹⁰, Bernard Combe¹¹, Emmanuelle Dernis Labous¹², Liana Euller-Ziegler¹³, Rene-Marc Flipo¹⁴, Philippe Gaudin¹⁵, Melanie Gilson¹⁶, Sandrine Guis¹⁷, Xavier Mariette¹⁸, Gaël Mouterde¹⁹, Sophie Pouplin²⁰, Pascal Richette²¹, Alain Saraux²², Thierry Schaeverbeke²³, Jean Sibilia²⁴, Françoise Fayet²⁵ and Maxime Dougados²⁶, ¹Rheumatology, Pitié Salpêtrière Hospital, Paris, France, ²Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ³COMEDRA working group, Paris, France, ⁴Hopital Cochin, Paris Descartes University, Paris, France, ⁵Hôpital Lariboisière, Paris, France, ⁶Rheumatology dept, APHP St-Antoine hospital, Univ Paris 06, Paris, France, Paris, France, ⁷Purpan Hospital, Toulouse, France, ⁸University Hospital, Toulouse, France, ⁹CHU RENNES, Rennes, France, ¹⁰University Hospital, Nancy, France, ¹¹Lapeyronie Hospital, Montpellier, France, ¹²Le Mans Hospital, Le Mans, France, ¹³Rheumatology, Nice, France, ¹⁴Rheumatology, University Hospital, Lille, France, ¹⁵Rheumatology, Grenoble University Hospital, France, Grenoble, France, ¹⁶Hopital Sud, Grenoble, France, ¹⁷Rheumatology 1, CRMBM-CEMEREM 7339, Aix-Marseille Université, AP-HM, CNRS, Marseilles, France, ¹⁸Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France, ¹⁹Rheumatology Department, Hopital Lapeyronie, Montpellier, France, ²⁰Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ²¹Rhumatologie, Hôpital Lariboisière, Paris, France, ²²Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ²³Rheumatology, CHU Bordeaux, Bordeaux, France, ²⁴Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²⁵Rheumatology, CHU Gabriel-Montpied, Clermont-Ferrand, France, ²⁶Cochin Hospital and Paris 05 University, Paris, France
Background/Purpose: Influenza and pneumococcal vaccinations are recommended in all patients with RA. However, it is well known that a gap exists between recommendations and their…
Abstract Number: 83 • 2016 ACR/ARHP Annual Meeting
A Qualitative Study Exploring Participants’ Perception of the Making It Work Program, an Online Program to Help People with Inflammatory Arthritis Maintain Employment
Xi yuan Li^1,2, Pam Rogers¹, Catherine L. Backman^1,3, Charles H. Goldsmith^4,5, Monique Gignac^6,7, Linda Li^1,8, John Esdaile^1,9 and Diane Lacaille^1,9, ¹Rheumatology, Arthritis Research Canada, Richmond, BC, Canada, ²Department of Cellular & Physiological Sciences, The University of British Columbia, Vancouver, BC, Canada, ³Department of Occupational Science & Occupational Therapy, The University of British Columbia, Vancouver, BC, Canada, ⁴Health Sciences, Simon Fraser University, Burnaby, BC, Canada, ⁵The University of British Columbia, Vancouver, BC, Canada, ⁶Institute of Work and Health, Toronto, ON, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸Department of Physical Therapy, The University of British Columbia, Vancouver, BC, Canada, ⁹Department of Medicine, Division of Rheumatology, The University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Health services addressing employment needs for people with arthritis are lacking. To address this need, we developed the Making it Work (MiW) program, an…
Abstract Number: 2050 • 2016 ACR/ARHP Annual Meeting
Screening for and Management of Comorbidities after a Nurse-Led Program: Results of a 3 Year Longitudinal Study in 776 Established RA Patients
Laure Gossec¹, Martin Soubrier², Frantz Foissac³, Anna Molto⁴, Françoise Fayet⁵, Thomas Bardin⁶, Francis Berenbaum⁷, Alain Cantagrel⁸, Marie Hélène Cerato⁹, Gerard H. Chales¹⁰, Bernard Combe¹¹, Emmanuelle Dernis Labous¹², Isabelle Chary-Valckenaere¹³, Liana Euller-Ziegler¹⁴, Rene-Marc Flipo¹⁵, Philippe Gaudin¹⁶, Melanie Gilson¹⁷, Sandrine Guis¹⁸, Xavier Mariette¹⁹, Gaël Mouterde²⁰, Sophie Pouplin²¹, Pascal Richette²², Alain Saraux²³, Thierry Schaeverbeke²⁴, Jean Sibilia²⁵ and Maxime Dougados²⁶, ¹Rheumatology, Pitié Salpêtrière Hospital, Paris, France, ²Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ³COMEDRA working group, Paris, France, ⁴Hopital Cochin, Paris Descartes University, Paris, France, ⁵Rheumatology, CHU Gabriel-Montpied, Clermont-Ferrand, France, ⁶Hôpital Lariboisière, Paris, France, ⁷Rheumatology dept, APHP St-Antoine hospital, Univ Paris 06, Paris, France, Paris, France, ⁸Purpan Hospital, Toulouse, France, ⁹University Hospital, Toulouse, France, ¹⁰CHU RENNES, Rennes, France, ¹¹Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ¹²Le Mans Hospital, Le Mans, France, ¹³University Hospital, Nancy, France, ¹⁴Rheumatology, Nice, France, ¹⁵Rheumatology, University Hospital, Lille, France, ¹⁶Rheumatology, Grenoble University Hospital, France, Grenoble, France, ¹⁷Hopital Sud, Grenoble, France, ¹⁸Rheumatology 1, CRMBM-CEMEREM 7339, Aix-Marseille Université, AP-HM, CNRS, Marseilles, France, ¹⁹Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France, ²⁰Rheumatology Department, Hopital Lapeyronie, Montpellier, France, ²¹Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ²²Rhumatologie, Hôpital Lariboisière, Paris, France, ²³Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ²⁴Rheumatology, CHU Bordeaux, Bordeaux, France, ²⁵Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²⁶Paris Descartes University, Paris, France
Background/Purpose: Patients with RA are either more at risk of, or less well screened for, several comorbidities including cardiovascular (CV) risk, cancer, infections and osteoporosis.[1]…
Abstract Number: 363 • 2016 ACR/ARHP Annual Meeting
An Examination of Patient Knowledge and Education in Patients with Osteoporosis, Osteopenia and Normal Bone Mineral Density
Shazia Beg¹ and Ahdad Ziyar², ¹University of Central Florida College of Medicine, Orlando, FL, ²University of Central Florida, Orlando, FL
Background/Purpose: Osteoporosis represents a preventable and often treatable condition that is responsible for 1.5 million fractures annually in the United States. Proper patient knowledge represents…
Abstract Number: 2084 • 2016 ACR/ARHP Annual Meeting
Effects of a Web-Based Patient Decision Aid on Biologics for Rheumatoid Arthritis: A Proof-of-Concept Study
Linda Li¹, Chris Shaw², Diane Lacaille¹, Elaine Yacyshyn³, C. Allyson Jones⁴, Paul Adam⁵, Cheryl Koehn⁶, Alison Hoens⁷, Jasmina Geldman⁸, Charles Goldsmith⁹, Eric C. Sayre⁸ and Nick Bansback¹⁰, ¹Rheumatology, Arthritis Research Canada, Richmond, BC, Canada, ²School of Interactive Arts and Technology, Simon Fraser University, Surrey, BC, Canada, ³University of Alberta, Edmonton, AB, Canada, ⁴Physical Therapy, University of Alberta, Edmonton, AB, Canada, ⁵Mary Pack Arthritis Program, Vancouver, BC, Canada, ⁶Arthritis Consumer Experts, Vancouver, BC, Canada, ⁷Dept of Physical Therapy, University of British Columbia, Vancouver, BC, Canada, ⁸Arthritis Research Canada, Richmond, BC, Canada, ⁹Faculty of Health Sciences, Simon Fraser University, Vancouver, BC, Canada, ¹⁰School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
Background/Purpose : Under the treat-to-target approach for patients with rheumatoid arthritis (RA), a biologic agent is considered when the target is not met despite trying…
Abstract Number: 421 • 2016 ACR/ARHP Annual Meeting
Educating Patients on the Cardiovascular Risks of Rheumatoid Arthritis: Usual Care Versus a Structured Approach
Marcia Genta¹ and Robert M. Genta², ¹Dallas Arthritis Center, Dallas, TX, ²Laboratory, Dallas Arthritis Center, Dallas, TX
Background/Purpose: Rheumatoid Arthritis (RA) carries a considerable increase of the risks for cardiovascular (CV) disease. It is unclear how well patients with RA understand such…
Abstract Number: 2239 • 2016 ACR/ARHP Annual Meeting
Patterns of Abatacept Utilization in Patients with Rheumatoid Arthritis. Have the Baseline Characteristics of These Patients Changed over Time?
M. Victoria Hernández¹, Carlos Sánchez-Piedra², Jose Inciarte-Mundo¹, Fernando Sanchez-Alonso², Javier Manero³, Rosa Roselló⁴, Eva Pérez-Pampin⁵, Rosa Morla⁶, Carlos Rodriguez-Lozano⁷, Dolores Ruiz-Montesinos⁸, Raimon Sanmarti¹, Juan J. Gómez-Reino⁵ and BIOBADASER 2.0 Study Group, ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ³Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ⁴Rheumatology, H San Jorge, Huesca, Spain, ⁵Rheumatology, Hospital Clínico Universitario. Santiago de Compostela, Santiago de Compostela, Spain, ⁶Arthritis Unit. Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ⁷Rheumatology, Hospital de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain, ⁸Rheumatology, Hospital Virgen Macarena, Seville, Spain
Background/Purpose: Abatacept (ABA), a T cell co-stimulation inhibitor, was initially approved by the European Medicine Agency (EMA) for patients with rheumatoid arthritis (RA) who had…
Abstract Number: 456 • 2016 ACR/ARHP Annual Meeting
Patient Engagement in Research: Understanding Patient Interest and Needs
Jennifer R. Horonjeff¹, Emily L. Creek² and Cindy McDaniel³, ¹Rheumatology, Columbia University Medical Center, New York, NY, ²Consumer Health, Arthritis Foundation, Atlanta, GA, ³Arthritis Foundation, Atlanta, GA
Background/Purpose: The goal of clinical and health-related research is to benefit the end-consumer—the patient. Since patients are the experts on their unique experiences living with…
Abstract Number: 2533 • 2016 ACR/ARHP Annual Meeting
Are There Differences in Baseline Comorbidities Between Rheumatoid Arthritis Patients Treated with Abatacept and Those Treated with Tumor Necrosis Factor Inhibitors?
M. Victoria Hernández¹, Carlos Sánchez-Piedra², Jose Inciarte-Mundo¹, Fernando Sanchez-Alonso², Javier Manero³, Rosa Roselló⁴, Eva Pérez-Pampin⁵, Carlos Rodriguez-Lozano⁶, Cesar Diaz-Torné⁷, Raimon Sanmarti¹, Juan J. Gómez-Reino⁵ and Biobadaser 2.0 Study Group, ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ³Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ⁴Rheumatology, H San Jorge, Huesca, Spain, ⁵Rheumatology, Hospital Clínico Universitario. Santiago de Compostela, Santiago de Compostela, Spain, ⁶Rheumatology, Hospital de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain, ⁷Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Background/Purpose: Rheumatoid arthritis (RA) patients frequently report concomitant comorbidities that could worsen their prognosis. Tumor necrosis factor inhibitors (TNFi), the most common biological agents used,…
Abstract Number: 628 • 2016 ACR/ARHP Annual Meeting
Analysis of Baseline Characteristics of Rheumatoid Arthritis Patients Treated with Abatacept Compared to Those Treated with Tumor Necrosis Factor Inhibitors in Clinical Practice
M. Victoria Hernández¹, Carlos Sánchez-Piedra², Juan D. Cañete¹, Fernando Sanchez-Alonso², Javier Manero³, Ana M. Ortiz Garcia⁴, Eva Pérez-Pampin⁵, Rosa Roselló⁶, Carlos Rodriguez-Lozano⁷, Raimon Sanmarti¹, Juan J. Gómez-Reino⁵ and BIOBADASER 2.0 Study Group, ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ³Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ⁴Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁵Rheumatology, Hospital Clínico Universitario. Santiago de Compostela, Santiago de Compostela, Spain, ⁶Rheumatology, H San Jorge, Huesca, Spain, ⁷Rheumatology, Hospital de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
Background/Purpose: Currently, the most widely used biological agents for rheumatoid arthritis (RA) patients are the inhibitors of the tumor necrosis factor (TNFi), although other biological…
Abstract Number: 3130 • 2016 ACR/ARHP Annual Meeting
Development and Pilot Testing of an Online Educational Tool for Gout Patients — Mygoutcare®
Puja Khanna¹, Aaron Rankin², Veronica Berrocal³, Larry An⁴ and Dinesh Khanna⁵, ¹Rheumatology, University of Michigan, Ann Arbor, MI, ²Medicine Rheumatology, University of Michigan, Ann Arbor, MI, ³Biostatistics, University of Michigan, Ann Arbor, MI, ⁴Medicine, University of Michigan, Ann Arbor, MI, ⁵University of Michigan, Ann Arbor, MI
Background/Purpose: Recent management guidelines for gout have identified several unmet educational needs in gout patients. Qualitative studies have documented the paucity of patient-focused materials which…
Abstract Number: 903 • 2016 ACR/ARHP Annual Meeting
Temporal Arteritis: Is There Any Correlation Between Ultrasonographic Arterial Wall Involvement and the Inflammatory Cellular Infiltrate at Histological Examination?
Giuseppe Germanò¹, Pierluigi Macchioni², Alberto Cavazza³, Niccolò Possemato², Mariagrazia Catanoso⁴, Luca Cimino⁵ and Carlo Salvarani⁶, ¹Unit of Rheumatology, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, ²Rheumatology Service, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ³Pathology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁴Rheumatology Service, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁵Ophthalmology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁶Rheumatology Unit, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy
Background/Purpose: Ultrasonographic alterations such as the halo sign and the compression test are now accepted as surrogate markers of artery inflammation. No data have yet…
Abstract Number: 981 • 2016 ACR/ARHP Annual Meeting
Effectiveness of a Six-Week Hand Osteoarthritis Program in a Primary Care Setting
Nina Brodin^1,2, Linda Bjurehed³ and Mathilda Björk^4,5, ¹Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy, Karolinska Institutet, Huddinge, Sweden, ²Department of Orthopaedics, Division of Physiotherapy, Dandeyd Hospital, Stockholm, Sweden, ³Department of Activity and Health, Linköping, Linköping University Hospital, Linköping, Sweden, ⁴Department of Rheumatology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, ⁵Department of Rheumatology and Department of Social and Welfare Studies, Linköping University, Linköping, Sweden
Background/Purpose: Hand Osteoarthritis (hand OA) is highly prevalent among women and men aged 55 and older. It often causes pain, reduced range of motion and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].